Table 8.
PAD-4 level (pg/mL) between treatments: MTX (therapy 1, n = 20), anti-TNFα (therapy 2, n = 20) and anti-IL-17A (therapy 3, n = 10) in patients with plaque psoriasis at three measurement points (week 0, week 4, week 12). * indicates a statistically significant difference (p < 0.05).
| PAD-4 | Week 0 | Week 4 | Effect (↓) | Week 12 | Effect (↓) |
|---|---|---|---|---|---|
| Therapy 1 | 686.92 ± 20.8 | 225.61 ± 19.3 | * 67% | 206.52 ± 18.2 | * 69% |
| Therapy 2 | 783.89 ± 11.34 | 223.26 ± 4.1 | * 71% | 148.1 ± 2.8 | * 81% |
| Therapy 3 | 1245.1 ± 57.6 | 568.0 ± 45.47 | * 54% | 539.0 ± 45.3 | * 56% |